NATCO Pharma Limited (NSE: NATCOPHARM)

India flag India · Delayed Price · Currency is INR
1,371.50
-17.05 (-1.23%)
Dec 24, 2024, 3:29 PM IST
73.13%
Market Cap 245.65B
Revenue (ttm) 45.64B
Net Income (ttm) 19.45B
Shares Out 179.11M
EPS (ttm) 108.58
PE Ratio 12.63
Forward PE 11.82
Dividend 5.75 (0.41%)
Ex-Dividend Date Nov 27, 2024
Volume 319,357
Open 1,393.85
Previous Close 1,388.55
Day's Range 1,367.25 - 1,399.00
52-Week Range 788.05 - 1,639.00
Beta 0.51
Analysts n/a
Price Target n/a
Earnings Date Feb 11, 2025

About NATCO Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosph... [Read more]

Sector Healthcare
Founded 1981
Employees 4,016
Stock Exchange National Stock Exchange of India
Ticker Symbol NATCOPHARM
Full Company Profile

Financial Performance

In 2023, NATCO Pharma's revenue was 40.02 billion, an increase of 47.76% compared to the previous year's 27.09 billion. Earnings were 13.88 billion, an increase of 94.09%.

Financial Statements

News

Natco Pharma reports 90.8% YoY export growth in November

Natco Pharma has delivered remarkable export growth for November 2024, marking a standout performance among API and formulation companies. The company recorded a significant 90.8% year-over-year (YoY)...

13 days ago - Business Upturn

Natco Pharma shares rise after selling Telangana land for Rs 115.6 crore

Shares of Natco Pharma edged up 1.01% to ₹1,364.90 in early trading today, following the company’s announcement of selling a 14.38-acre land parcel in Telangana for ₹115.57 crore. The transaction incl...

27 days ago - Business Upturn

Natco Pharma sells Telangana land for ₹115.57 crore

Natco Pharma Limited has announced the sale of a 14.38-acre land parcel, equivalent to 72,358 square yards, located at Mekaguda Gram Panchayat, Nandigama Mandal, Ranga Reddy District, Telangana.

27 days ago - Business Upturn

Natco Pharma submits ANDA for Risdiplam for oral solution

Natco Pharma has announced its submission of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification to the U.S. FDA for the generic version of EVRYSDI® (Risdiplam) 0.75 mg/mL Ora...

4 weeks ago - Business Upturn

Natco Pharma Q2 FY24-25 Results: Revenue rises 32.1% YoY to ₹1,371 crore, profit surges 81.2% to ₹676.5 crore

Natco Pharma Limited has reported strong financial results for the second quarter ended September 30, 2024, showcasing significant growth in both revenue and profitability. Quarterly Financial Highlig...

6 weeks ago - Business Upturn

Natco Pharma Q2 FY25 results: Stock surge over 2% ahead of result announcement

Shares of Natco Pharma saw a notable rise of over 2%, reaching an intraday high of ₹1,435.40, as investors eagerly anticipate the company’s upcoming Q2 FY25 results. The stock opened at ₹1,402.00 and ...

6 weeks ago - Business Upturn

Q2 results today: Hyundai Motor India, Bosch, Zydus Lifesciences, Nykaa, Unno Minda, 3M India, Natco Pharma, TBO Tek among companies to announce earnings

A diverse group of companies, including Hyundai Motor India, Bosch, Zydus Lifesciences, and FSN E-Commerce Ventures (Nykaa), are set to announce their Q2 FY24-25 financial results today. Here’s a list...

6 weeks ago - Business Upturn

Health groups join patent war over spinal muscular atrophy drug

Public health groups are challenging Roche's attempt to block a generic version of its expensive Spinal Muscular Atrophy drug, Risdiplam. They argue that Roche's patent infringement lawsuit against Na...

7 weeks ago - The Times of India

Pharma stocks today: Gland Pharma rises 1.53%, Aurobindo Pharma up 1.38%, while Natco Pharma falls 1.40%, and Laurus Labs down 1.41%

As of 10:31 AM, the pharma sector has witnessed both gains and losses. Gland Pharma is the top gainer, rising by 1.53% to ₹1,675.40, followed by Aurobindo Pharma, up 1.38% at ₹1,493.00. Mankind Pharma...

2 months ago - Business Upturn

Pharma Stocks Update: Check out how Cipla, Lupin, Abbott India, Divi’s Lab, Zydus Life, Dr Reddy’s Lab are performing today

JB Chem rises 1.91%, Biocon gains 0.87%, while Natco Pharma drops 2.65% and Gland Pharma slips 1.38% in today's trade.

2 months ago - Business Upturn

Top Morning Losers Today: Home First, RITES, ICICI Securities, Natco Pharma, Thermax lead declines [Oct 10]

Several stocks are facing downward pressure in the morning session as of 10:41 AM. Here are the top losers: Home First Finance (HOMEFIRST): The stock fell by 4.90%, trading at ₹1,245.25, down ₹64.10. ...

2 months ago - Business Upturn

Pharma Stocks Update: Natco Pharma gains 2.99%, Glenmark rises 0.07%, Granules falls 3.83%

As of 2:38 PM, the Nifty Pharma index saw a mixed performance with some stocks showing notable gains while others faced losses. Natco Pharma, Glenmark, and Ajanta Pharma were the top gainers, while Gr...

2 months ago - Business Upturn

NATCO Pharma shares surge 3% after announcing settlement in U.S. patent litigation

NATCO Pharma shares jumped more than 3% in morning trade after the company announced that Mylan Pharmaceuticals Inc. and Novo Nordisk had settled a U.S. patent litigation concerning developing a gener...

2 months ago - Business Upturn

NATCO Pharma announces settlement in U.S. patent litigation for generic Ozempic

NATCO Pharma Limited has announced that Mylan Pharmaceuticals Inc. and Novo Nordisk have settled a U.S. patent litigation concerning the development of a generic version of Ozempic (Semaglutide). The ...

2 months ago - Business Upturn

Natco Pharma stock surges over 4% after submitting FDA application for lung cancer treatment

Natco Pharma (NATCOPHARM) shares surged by 4.19%, trading at ₹1,562.00 at 9:59 AM, following the company’s announcement of submitting a product application to the U.S. Food and Drug Administration (FD...

4 months ago - Business Upturn

Natco Pharma submits ANDA for generic version of Tabrecta, a $126M US market drug

Natco Pharma Limited has submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) for a generic version of Tabrecta (Capmatinib hydrochloride). The applicati...

4 months ago - Business Upturn

Q1 2025 Natco Pharma Ltd Earnings Call Transcript

Q1 2025 Natco Pharma Ltd Earnings Call Transcript

4 months ago - GuruFocus